Adults with Down syndrome develop the neuropathological hallmarks of Alzheimer's
disease and are at very high risk of developing early-onset dementia, which is now the …

BACKGROUND: Recent advances in medical care have increased life expectancy and
improved the quality of life for people with Down syndrome (DS). These advances are the …

Improved medical care of individuals with Down syndrome (DS) has led to an increase in life
expectancy to over the age of 60 years. In conjunction, there has been an increase in age …

Down syndrome (DS) is one of the most well-recognized genetic disorders. Persons with DS
are known to have a variety of co-morbid medical problems, affecting nearly all organ …

The association between white matter hyperintensities (WMH) and amyloid accumulation
over time in cognitively normal, amyloid-negative elderly people remains largely …

Epidemiological evidence suggests that by the age of 40 years, all individuals with Down
syndrome (DS) have Alzheimer's disease (AD) neuropathology. Clinical diagnosis of …

The increased life expectancy of individuals with Down syndrome (DS) is associated with
increased prevalence of trisomy 21–linked early-onset Alzheimer's disease (EOAD) and …

Objective To determine whether treatment with escitalopram compared with placebo would
lower CSF β-amyloid 42 (Aβ42) levels. Rationale Serotonin signaling suppresses Aβ42 in …

The purpose of this review is to compare and highlight the clinical and pathological aspects
of genetic versus acquired Alzheimer's disease: Down syndrome-associated Alzheimer's …

Background: Alzheimer's disease (AD) is a chronic neurodegenerative disease and the most
common form of dementia, especially in the elderly. Due to the increase in life expectancy, in …